EP1115422A4 - Use of non-peptidyl compounds for the treatment of insulin related ailments - Google Patents

Use of non-peptidyl compounds for the treatment of insulin related ailments

Info

Publication number
EP1115422A4
EP1115422A4 EP99947113A EP99947113A EP1115422A4 EP 1115422 A4 EP1115422 A4 EP 1115422A4 EP 99947113 A EP99947113 A EP 99947113A EP 99947113 A EP99947113 A EP 99947113A EP 1115422 A4 EP1115422 A4 EP 1115422A4
Authority
EP
European Patent Office
Prior art keywords
treatment
insulin related
peptidyl compounds
related ailments
ailments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99947113A
Other languages
German (de)
French (fr)
Other versions
EP1115422A1 (en
Inventor
Erik Helmerhorst
Brian Scott Plewright
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Curtin University of Technology
Original Assignee
Curtin University of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curtin University of Technology filed Critical Curtin University of Technology
Publication of EP1115422A1 publication Critical patent/EP1115422A1/en
Publication of EP1115422A4 publication Critical patent/EP1115422A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP99947113A 1998-09-22 1999-09-17 Use of non-peptidyl compounds for the treatment of insulin related ailments Withdrawn EP1115422A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPP609198 1998-09-22
AUPP6091A AUPP609198A0 (en) 1998-09-22 1998-09-22 Use of non-peptidyl compounds for the treatment of insulin related ailments
PCT/AU1999/000786 WO2000016798A1 (en) 1998-09-22 1999-09-17 Use of non-peptidyl compounds for the treatment of insulin related ailments

Publications (2)

Publication Number Publication Date
EP1115422A1 EP1115422A1 (en) 2001-07-18
EP1115422A4 true EP1115422A4 (en) 2003-01-29

Family

ID=3810308

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99947113A Withdrawn EP1115422A4 (en) 1998-09-22 1999-09-17 Use of non-peptidyl compounds for the treatment of insulin related ailments

Country Status (4)

Country Link
EP (1) EP1115422A4 (en)
AU (1) AUPP609198A0 (en)
CA (1) CA2345155A1 (en)
WO (1) WO2000016798A1 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001247459A (en) 2000-03-03 2001-09-11 Oakland Uniservices Ltd Combination therapy for cancer
WO2002009700A1 (en) 2000-07-28 2002-02-07 Cancer Research Technology Limited Cancer treatment by combination therapy
EP1324995A2 (en) 2000-09-27 2003-07-09 Merck & Co., Inc. Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders
EP1347755A2 (en) * 2000-10-31 2003-10-01 Merck & Co., Inc. Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders
US20110065129A1 (en) 2001-07-27 2011-03-17 Lowe Derek B Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
GB2386836B (en) 2002-03-22 2006-07-26 Cancer Res Ventures Ltd Anti-cancer combinations
US7087631B2 (en) 2002-07-18 2006-08-08 Inotek Pharmaceuticals Corporation Aryltetrazole compounds, and compositions thereof
US7078423B2 (en) 2002-07-18 2006-07-18 Inotek Pharmaceuticals Corporation 5-Aryltetrazole compounds, compositions thereof, and uses therefor
GB2394658A (en) 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
UA84035C2 (en) 2003-10-31 2008-09-10 Янссен Фармацевтика Н.В. Phenoxyacetic acids derivatives useful as peroxisome proliferator-activated receptor (ppar) dual agonists
FR2879458B1 (en) * 2004-12-21 2007-07-20 Centre Nat Rech Scient Cnrse FLUORINATED SULFAMIDES AND SULFINIMIDES
SI1945632T1 (en) 2005-11-08 2014-03-31 Vertex Pharmaceuticals Incorporated Heterocyclic modulators of atp-binding cassette transporters
US7671221B2 (en) 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US7754739B2 (en) 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
JP5497633B2 (en) 2007-05-09 2014-05-21 バーテックス ファーマシューティカルズ インコーポレイテッド CFTR modulator
WO2009073757A1 (en) 2007-12-07 2009-06-11 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
WO2009076142A2 (en) 2007-12-07 2009-06-18 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxiamido-pyridine benzoic acids
CA3039943C (en) 2008-02-28 2021-07-13 Vertex Pharmaceuticals Incorporated Heteroaryl derivatives as cftr modulators
US8138208B2 (en) 2008-07-15 2012-03-20 Hoffmann-La Roche Inc. Aminotetrahydroindazoloacetic acids
US8124641B2 (en) 2008-07-15 2012-02-28 Hoffmann-La Roche Inc. Aminotetrahydroindazoloacetic acids
JP2012500189A (en) 2008-08-15 2012-01-05 エフ．ホフマン−ラ ロシュ アーゲー Biarylaminotetralin
JP5302398B2 (en) 2008-08-15 2013-10-02 エフ．ホフマン−ラ ロシュ アーゲー Substituted aminotetralin
US8188090B2 (en) 2008-11-17 2012-05-29 Hoffman-La Roche Inc. Naphthylacetic acids
CN102216249A (en) 2008-11-17 2011-10-12 霍夫曼-拉罗奇有限公司 Naphthylacetic acids
SG171734A1 (en) 2008-11-17 2011-07-28 Hoffmann La Roche Naphthylacetic acids
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
CA2795804C (en) 2010-04-07 2021-10-26 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof
KR20130056244A (en) 2010-04-22 2013-05-29 버텍스 파마슈티칼스 인코포레이티드 Process of producing cycloalkylcarboxamido-indole compounds
ES2587856T3 (en) 2011-03-18 2016-10-27 Ono Pharmaceutical Co., Ltd. Tetrahydrocarboline derivative
US8470884B2 (en) 2011-11-09 2013-06-25 Hoffmann-La Roche Inc. Alkenyl naphthylacetic acids
CA2930199C (en) 2013-11-12 2022-10-25 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of cftr mediated diseases
PL3925607T3 (en) 2014-04-15 2023-10-30 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
PT3221692T (en) 2014-11-18 2021-09-10 Vertex Pharma Process of conducting high throughput testing high performance liquid chromatography

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2037002A1 (en) * 1969-04-30 1970-12-31 Roques Bernard N-substd biguanide pamoic acid salts prepn
WO1990015816A1 (en) * 1989-06-16 1990-12-27 The Upjohn Company Suramin type compounds and angiostatic steroids to inhibit angiogenesis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5105017A (en) * 1983-07-18 1992-04-14 Eli Lilly And Company Leukotriene antagonist intermediates
DK113585D0 (en) * 1985-03-12 1985-03-12 Novo Industri As NEW PEPTIDES
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
CA1339416C (en) * 1987-02-25 1997-09-02 Liselotte Langkjaer Insulin derivatives
ATE93238T1 (en) * 1988-07-20 1993-09-15 Novo Nordisk As HUMAN INSULIN PLANTS AND PREPARATIONS THEREOF.
JPH04502465A (en) * 1988-12-23 1992-05-07 ノボ　ノルディスク　アクティーゼルスカブ human insulin analogue
ATE120762T1 (en) * 1989-04-20 1995-04-15 Sinai School Medicine HEPATO-SPECIFIC INSULIN ANALOGUE.
US5478857A (en) * 1993-12-23 1995-12-26 Eli Lilly And Company Use of PLA2 inhibitors as treatment for alzheimer's disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2037002A1 (en) * 1969-04-30 1970-12-31 Roques Bernard N-substd biguanide pamoic acid salts prepn
WO1990015816A1 (en) * 1989-06-16 1990-12-27 The Upjohn Company Suramin type compounds and angiostatic steroids to inhibit angiogenesis

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"[A new salt of metformin proposed in the oral treatment of diabetes: embonate (or pamoate) of metformin]", JOURNEES ANNUELLES DE DIABETOLOGIE DE L'HOTEL-DIEU. FRANCE 1977, 1977, pages 382 - 385, XP000913584, ISSN: 0075-4439 *
AUBERT: "oral antidiabetic...", SCIENCES MEDICALES, vol. 10, no. 47, 1980, pages 31 - 32, XP008010780 *
KLIJN J G ET AL: "Growth factor-receptor pathway interfering treatment by somatostatin analogs and suramin: preclinical and clinical studies.", THE JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY. ENGLAND 20 DEC 1990, vol. 37, no. 6, 20 December 1990 (1990-12-20), pages 1089 - 1095, XP008010776, ISSN: 0960-0760 *
LUNDQUIST I: "Islet lysosomal enzyme activities and plasma insulin levels in obese hyperglycemic mice following injection of the lysosomotropic drug suramin.", DIABETES RESEARCH (EDINBURGH, LOTHIAN) SCOTLAND JUL 1985, vol. 2, no. 4, July 1985 (1985-07-01), pages 207 - 211, XP008010803, ISSN: 0265-5985 *
See also references of WO0016798A1 *
SETYONOHAN B (REPRINT) ET AL: "SURAMIN - PHARMACOKINETIC MONITORING, HEMATOLOGICAL AND ANTITUMOR EFFECTS ON RATS BEARING TRANSPLANTABLE PANCREATIC TUMORS", EUROPEAN JOURNAL OF CANCER, (1990) VOL. 26, NO. 2, PP. 184., DR DANIEL DENHOED CANC CTR, DIV ENDOCRINE ONCOL, ROTTERDAM, NETHERLANDS, XP008010849 *

Also Published As

Publication number Publication date
WO2000016798A1 (en) 2000-03-30
CA2345155A1 (en) 2000-03-30
EP1115422A1 (en) 2001-07-18
AUPP609198A0 (en) 1998-10-15

Similar Documents

Publication Publication Date Title
EP1115422A4 (en) Use of non-peptidyl compounds for the treatment of insulin related ailments
IL196301A0 (en) Medicament for the treatment of hapatitis c
HK1041807A1 (en) Cartridge for medical liquid
HUP0103621A3 (en) Fentanyl composition for the treatment of acute pain
HUP0103856A3 (en) Pharmaceutical composition for the treatment of acute disorders
HK1047284A1 (en) 2-amino-benzoxazinone derivatives for the treatment of obesity
AU2935200A (en) Compounds for the treatment of obesity
IL151890A0 (en) Hydroxyphenyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
EP1077704A4 (en) Combination therapy for treatment of depression
AU7622000A (en) Compounds for the treatment of viral-mediated diseases
HUP0003428A3 (en) Use of leptin antagonists for the treatment of diabetes
IL151765A0 (en) Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain
IL151891A0 (en) Quinolinyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
GB9816234D0 (en) Compounds for use in the treatment of inflammation
IL148640A0 (en) Processes for the preparation of sumatriptan and related compounds
HUP0101947A3 (en) Combination for the treatment of tumors
IL133760A0 (en) Composition for the treatment of dandruff
AU2566201A (en) Compounds and methods for the treatment of pain
AU1940800A (en) Combination therapy for the treatment of sepsis
HUP0001891A3 (en) Medicament for the treatment of migraine
GB2332849B (en) Apparatus for the treatment of soil
HK1043938A1 (en) Composition for the treatment of psoriasis
GB9904252D0 (en) Composition for the treatment of pain
HUP0300313A3 (en) Compound, pharmaceutical composition containing it and its use for the treatment of pain
GB9704174D0 (en) Agent for medical treatment

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010418

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20021217

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61P 27/02 B

Ipc: 7A 61K 31/35 B

Ipc: 7A 61K 31/19 B

Ipc: 7A 61K 38/28 A

17Q First examination report despatched

Effective date: 20030926

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050920